TEAD inhibitory protein polypeptide TEAi for bone tissue regeneration and application

By developing the N-terminal protein polypeptide inhibitor TEAi, the problem that existing TEAD inhibitors cannot promote osteogenesis and differentiation of PDLSCs is solved, and significant bone tissue regeneration effect is achieved, especially in the craniomaxillofacial bone tissue defects. In treatment.

CN118909051AActive Publication Date: 2024-11-08STOMATOLOGICAL HOSPITAL TIANJIN MEDICAL UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410981461.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-08
Estimated Expiration
2044-07-22

AI Technical Summary

Technical Problem

Existing TEAD inhibitors fail to effectively promote osteogenic differentiation of periodontal membrane stem cells PDLSCs and mediate in vivo bone tissue regeneration, and lack effective small molecule drugs for craniomaxillofacial bone tissue defects.

Method used

TEAi, an N-terminal protein polypeptide inhibitor targeting TEAD, has developed an amino acid sequence of DITDGSMQYSNGDIDPKYNIVEITEETKAELAIKNVIGDYVCRLCKIKFEDAFGLARHRCA, which can significantly promote the osteogenic differentiation of PDLSCs and reverse the inhibitory effect of TEAD on osteogenic differentiation.

Benefits of technology

TEAi significantly promoted osteogenic differentiation and in vivo new bone formation of PDLSCs, reversed TEAD's inhibition of PDLSCs-mediated in vivo new bone formation and neogenous bone tissue mineralization, and provided effective polypeptide molecules for bone tissue regeneration, and applied to Clinical treatment of craniomaxillofacial bone tissue defects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909051A_ABST
    Figure CN118909051A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines and polypeptides, and discloses a TEAD inhibitory protein polypeptide TEAi for bone tissue regeneration, and the amino acid sequence of the TEAi is SEQ ID NO. 1. The protein polypeptide inhibitor (TEAi) targeting the N end of TEAD is selected and applied for the first time, and PDLSCs osteogenic differentiation and in-vivo bone tissue regeneration mediated by the PDLSCs osteogenic differentiation are promoted. Effective polypeptide molecules are provided for stem cell-mediated bone tissue regeneration, so that the stem cell-mediated bone tissue regeneration polypeptide is applied clinically, and the bone tissue regeneration effect of a patient with cranio-maxillofacial bone tissue defect is promoted.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medicine and polypeptide technology, and in particular to a TEAD inhibitory protein polypeptide TEAi for bone tissue regeneration and its application. Background Art

[0002] The craniomaxillofacial bones support the facial contour and are closely related to physiological functions such as chewing, breathing and language. Various factors such as trauma, inflammation, tumors or congenital diseases can lead to craniomaxillofacial bone defects, causing them to lose continuity and integrity, thereby causing aesthetic problems and functional disorders. Tooth loosening and loss caused by alveolar bone absorption due to periodontitis has now become the primary cause of tooth loss in adults, seriously affecting patients' chewing function and quality of life. Therefore, seeking effective methods to repair bone tissue defects and promote craniomaxillofacial bone tissue regeneration is a key clinical issue in the field of stomatology.

[0003] In recent years, stem cells have shown good clinical application prospects in the treatment of diseases and tissue damage by promoting the repair and regeneration of damaged tissues. Among them, mesenchymal stem cells (MSCs) have attracted widespread attention due to their availability, ease of separation, multipotency, and low immunogenicity. Under appropriate culture conditions, MSCs can be selectively induced to differentiate into various lineages, such as osteoblasts, adipocytes, neurons, and myoblasts.

[0004] Periodontal ligament stem cells (PDLSCs) are a type of dental MSCs with self-renewal and multidirectional differentiation potential. At the same time, PDLSCs are rarely reported to be tumorigenic. They can maintain their typical phenotypic and karyotype characteristics during moderate subculture and have certain immunoregulatory abilities. When inflammation or defect occurs in the body's tissues, PDLSCs can respond to inflammatory signals, migrate to the defective tissue site and differentiate into corresponding cells, thereby promoting tissue repair and regeneration. In addition, PDLSCs also have unique advantages in angiogenesis, immunoregulation, and anti-inflammation. In recent years, PDLSCs have been considered to be a very promising stem cell population, and have been proven in animal experiments and clinical trials to be well applied to the maintenance and regeneration of bone tissue homeostasis. However, the bone tissue regeneration effect mediated by PDLSCs still fails to meet clinical needs, and there is also a lack of effective small molecule drugs. Therefore, it is of great clinical significance to seek effective small molecule drugs that promote the osteogenic differentiation of PDLSCs and promote the bone tissue regeneration mediated by them.

[0005] As a highly conserved signaling pathway in evolution, the Hippo signaling pathway plays an important regulatory role in cell proliferation and differentiation, the size of organismal organs, and tissue homeostasis and regeneration. The activation signal upstream of this pathway ultimately inhibits downstream YAP and TAZ through phosphorylation, thereby regulating the transcriptional output of target genes. As a transcriptional cofactor, YAP / TAZ itself lacks a DNA binding domain, and its function is largely dependent on the TEA domain transcription factor (TEAD) with DNA binding ability.

[0006] TEAD transcription factors can regulate organismal development by coordinating the transcription of target genes. Since their first discovery three decades ago, the importance of TEAD function has received widespread attention, and its research has mainly focused on its role in the Hippo signaling pathway. However, in recent years, many studies have shown that TEAD also plays a regulatory role in tissue development and human health and disease that is independent of the Hippo signaling pathway.

[0007] TEAD has now become an important developmental regulator, with functions such as regulating progenitor cell proliferation, stem cell fate and lineage differentiation, and plays an important role in tissue homeostasis and regeneration. In mammals, the TEAD family consists of TEAD1, TEAD2, TEAD3 and TEAD4. All four TEADs are highly conserved transcription factors in evolution and are widely expressed in embryonic and adult tissues. As a transcription factor, TEAD contains a highly conserved DNA binding domain (TEA domain) at its N-terminus, which has the function of binding to DNA, and a YAP-binding domain (YBD) at its C-terminus, which has the function of interacting with different cofactors.

[0008] TEAD itself does not have transcriptional activity, and it needs to bind to various cofactors to play a corresponding transcriptional regulatory role. Studies have found that TEAD can interact with RUNX2, inhibit the expression of osteogenesis-related genes downstream of RUNX2, and thus inhibit cell osteogenic differentiation. Therefore, targeted inhibition of TEAD can theoretically promote cell osteogenic differentiation.

[0009] However, most of the existing TEAD inhibitors target the C-terminus of TEAD and thus play an anti-tumor role, and no TEAD inhibitor has been applied to the osteogenic differentiation of PDLSCs and its mediated bone tissue regeneration in vivo. Summary of the invention

[0010] The purpose of the present invention is to overcome the deficiencies in the prior art and provide a TEAD inhibitory protein polypeptide TEAi for bone tissue regeneration and its application.

[0011] The technical solution adopted by the present invention to solve its technical problem is:

[0012] A TEAD inhibitory protein polypeptide TEAi for bone tissue regeneration, wherein the amino acid sequence of the TEAi is: SEQ ID NO.1.

[0013] Furthermore, the TEAi can significantly promote the osteogenic differentiation of human periodontal ligament stem cells PDLSCs, and TEAi can reverse the inhibitory effect of TEAD on the osteogenic differentiation of PDLSCs.

[0014] Furthermore, the TEAiTEAi can reverse the inhibitory effect of TEAD3 on the in vivo new bone formation ability mediated by PDLSCs.

[0015] Furthermore, the TEAi can reverse the inhibitory effect of TEAD3 on the mineralization of new bone tissue mediated by PDLSCs in vivo.

[0016] The use of TEAi as described above for bone tissue regeneration.

[0017] Furthermore, the bone tissue regeneration is the osteogenic differentiation of human periodontal ligament stem cells and the bone tissue regeneration mediated by them in vivo.

[0018] Use of the TEAi as described above in the preparation of a medicament and / or product and / or preparation for bone tissue regeneration.

[0019] Use of the TEAi as described above in the preparation of a drug and / or product and / or preparation for osteogenic differentiation of human periodontal ligament stem cells and the in vivo bone tissue regeneration mediated by the same.

[0020] The advantages and positive effects achieved by the present invention are:

[0021] 1. The present invention selects and applies for the first time a protein polypeptide inhibitor (TEAi) targeting the N-terminus of TEAD to promote osteogenic differentiation of PDLSCs and its mediated bone tissue regeneration in vivo. Protein polypeptide sequence: DITDGSMQYSNGDIDPKYNIVEITEETKAELAAIKNVIGDYVCRLCKIKFEDAFGLARHRCA CI

[0022] 2. The present invention provides effective polypeptide molecules for stem cell-mediated bone tissue regeneration, which can be applied clinically to promote bone tissue regeneration in patients with craniomaxillofacial bone tissue defects.

[0023] 3. The difference between targeting the N-terminus and the C-terminus: As a transcription factor, the function of TEAD depends on both DNA binding activity and binding to other transcription cofactors, but TEAD can bind to different transcription cofactors, so it is difficult to disrupt the binding of all transcription cofactors with tumor-promoting functions by targeting the C-terminus. In addition, the TEAD C-terminus will also bind to the VGLL4 protein with tumor suppressor function, so targeting the C-terminus will also disrupt the function of the TEAD-VGLL4 tumor suppressor complex. In comparison, targeting the DNA binding domain of TEAD can theoretically inhibit TEAD-mediated tumor-promoting function to a greater extent. In addition, studies have shown that TEAD is not necessary for the survival of normal cells, so targeting the DNA binding domain of TEAD can both ensure its effectiveness and reduce interference with normal cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 Graph showing the effect of overexpression of TEAD on the osteogenic differentiation ability of PDLSCs in the present invention; wherein, A is ALP staining and ALP activity quantification after 7 days of osteogenic differentiation, scale bar: 200 μm; B is Alizarin red staining and calcium ion concentration quantification after 14 days of osteogenic differentiation, scale bar: 200 μm; C is RT-qPCR detection of mRNA expression levels of osteogenic-related genes after 7 days of osteogenic differentiation; OE-Vector: overexpression control group; OE-TEAD1: overexpression TEAD1 group; OE-TEAD2: overexpression TEAD2 group; OE-TEAD3: overexpression TEAD3 group; OE-TEAD4: overexpression TEAD4 group; *P<0.05, **P<0.01, ***P<0.001vs.OE-Vector;

[0025] Figure 2 Figure 1 is the effect of TEAD knockdown on the osteogenic differentiation ability of PDLSCs in the present invention; A is ALP staining and ALP activity quantification after 7 days of osteogenic differentiation, scale bar: 200 μm; B is Alizarin red staining and calcium ion concentration quantification after 14 days of osteogenic differentiation, scale bar: 200 μm; C is RT-qPCR detection of mRNA expression levels of osteogenic-related genes after 7 days of osteogenic differentiation; shScr: knockdown control group; shTEAD1: TEAD1 knockdown group; shTEAD2: TEAD2 knockdown group; shTEAD3: TEAD3 knockdown group; shTEAD4: TEAD4 knockdown group; *P<0.05, **P<0.01, ***P<0.001vs.shScr;

[0026] Figure 3The figure is the effect of TEAi on the osteogenic differentiation ability of PDLSCs in the present invention; wherein A is ALP staining and ALP activity quantification after 7 days of osteogenic differentiation, scale bar: 200 μm; B is Alizarin red staining and calcium ion concentration quantification after 14 days of osteogenic differentiation, scale bar: 200 μm; C is RT-qPCR detection of mRNA expression levels of osteogenic-related genes after 7 days of osteogenic differentiation; **P<0.01, ***P<0.001;

[0027] Figure 4 Schematic diagram of the establishment of the rat skull defect model in the present invention; black arrows: implantation of PDLSCs + carrier materials; scale bar: 5 mm;

[0028] Figure 5 The three-dimensional reconstruction and statistical analysis of the skull Micro-CT in the present invention; A is the three-dimensional reconstruction image of the skull Micro-CT, scale: 1mm; B is the statistical analysis: BV / TV: Bone volume / Tissue volume, bone volume fraction; Tb.Th: Trabecular thickness, trabecular thickness; Tb.N: Trabecular number, trabecular number; Tb.Sp: Trabecular separation, trabecular separation; # P<0.05vs.Vector; *P<0.05, **P<0.01, ***P<0.001;

[0029] Figure 6 These are diagrams showing the new bone formation ability of the bone defect areas in each group observed by tissue staining in the present invention; wherein A is HE staining; B is Masson staining; and C is OPN immunohistochemical staining and quantification. # P<0.05vs.Vector; *P<0.05, ***P<0.001. DETAILED DESCRIPTION

[0030] The present invention will be further described below in conjunction with the embodiments. The following embodiments are descriptive rather than restrictive, and the protection scope of the present invention cannot be limited by the following embodiments.

[0031] The various experimental operations involved in the specific embodiments are all routine techniques in the art. For parts not specially annotated in this document, ordinary technicians in the art can implement them by referring to various commonly used reference books, scientific and technological literature or related instructions, manuals, etc. before the filing date of this invention.

[0032] A TEAD inhibitory protein polypeptide TEAi for bone tissue regeneration, wherein the amino acid sequence of the TEAi is: SEQ ID NO.1.

[0033] Preferably, the TEAi can significantly promote the osteogenic differentiation of human periodontal ligament stem cells PDLSCs, and TEAi can reverse the inhibitory effect of TEAD on the osteogenic differentiation of PDLSCs.

[0034] Preferably, the TEAi can reverse the inhibitory effect of TEAD3 on the in vivo new bone formation ability mediated by PDLSCs.

[0035] Preferably, the TEAi can reverse the inhibitory effect of TEAD3 on the mineralization of new bone tissue in vivo mediated by PDLSCs.

[0036] The use of TEAi as described above for bone tissue regeneration.

[0037] Preferably, the bone tissue regeneration is osteogenic differentiation of human periodontal ligament stem cells and the bone tissue regeneration mediated by them in vivo.

[0038] Use of the TEAi as described above in the preparation of a medicament and / or product and / or preparation for bone tissue regeneration.

[0039] Use of the TEAi as described above in the preparation of a drug and / or product and / or preparation for osteogenic differentiation of human periodontal ligament stem cells and the in vivo bone tissue regeneration mediated by the same.

[0040] Specifically, the relevant preparation and detection are as follows:

[0041] 1. Extraction of human periodontal ligament stem cells (PDLSCs)

[0042] (1) Sample collection

[0043] The study samples were from patients aged 14 to 45 years with no history of periodontitis and good oral hygiene. The complete premolars or third molars extracted for orthodontic treatment, dental restoration or surgery were mainly selected, and the tooth tissues were free of caries. All patients were informed and signed informed consent. All excised teeth were obtained by chairside collection. After the teeth were extracted from the alveolar socket, they were immediately placed in a centrifuge tube containing PBS solution to avoid contamination and keep the root surface moist.

[0044] (2) Isolation and extraction of PDLSCs

[0045] 1) Prepare enzyme digestion solution

[0046] Take out the sealed neutral enzyme and type I collagenase from the 4℃ and -20℃ refrigerators, weigh 120mg of neutral enzyme and 90mg of type I collagenase, and put them into 15mL centrifuge tubes respectively, and mark the name of the enzyme on the tube wall. Then, transfer the centrifuge tubes to the clean bench, add 6mL of sterile PBS solution to each tube, shake and mix evenly, then adjust the total volume to 15mL with PBS solution, and mix again evenly. Use a 0.22μm filter membrane to filter the two solutions into new sterile centrifuge tubes to remove impurities. After that, divide them into sterile EP tubes, mark the name and preparation date on the tubes, seal them and store them in 4℃ and -20℃ refrigerators as required. Before the experiment, take out the packaged neutral enzyme and type I collagenase in advance as needed, and place them on ice after thawing for use. When using, mix the neutral enzyme and type I collagenase in equal volume ratio to prepare tissue digestion solution. In addition, all equipment required for the experiment was disinfected in advance, and the sterile operating table was exposed to ultraviolet light for more than 30 minutes. The distilled water in the constant temperature water bath was replaced and set to 37°C to provide a constant temperature environment for subsequent experimental operations.

[0047] 2) Isolation and extraction of PDLSCs

[0048] Prepare a PBS gradient irrigating solution with a volume concentration of 20%, 10%, and 5% penicillin-streptomycin in advance. Use tweezers to gently clamp the crown position, making sure that the root tip faces up and the crown faces down. Use PBS gradient irrigating solution from high concentration to low concentration, from top to bottom, to carefully rinse the periodontal ligament tissue at the root to completely remove the residual blood clots. Finally, use a large amount of PBS for rinsing. Then, take out the culture dish and add 100μL of sterile PBS solution. Use a sterile surgical blade to gently scrape 1 / 3 of the periodontal ligament tissue in the root, put it into the PBS in the culture dish, and then use a new sterile blade to repeatedly chop the periodontal ligament tissue. After that, use a pipette to carefully absorb the PBS containing the periodontal ligament tissue fragments into the prepared tissue digestion solution. Then, put it in a 37℃ water bath for digestion. Take out the centrifuge tube every 5 minutes for oscillation mixing, and observe its digestion. After digestion for 20–30 minutes, take out the centrifuge tube and spin centrifuge at 1000rpm for 4 minutes. Carefully remove the upper digestion solution, leaving only the tissue precipitate below, and resuspend the digested tissue precipitate in α-MEM medium containing 15% serum and 2% (conventional writing method in this field) double antibody (penicillin-streptomycin) and add it to the culture dish, cross-mix and culture. Do not take the culture dish repeatedly in a short period of time to avoid affecting the tissue adhesion effect. On the third day of culture, take out and check whether the culture medium is contaminated. On the fifth day, if cell growth is observed, remove the original culture medium, gently wash twice with PBS preheated at 37°C, and then add fresh α-MEM medium containing 10% serum and 1% double antibody. Replace fresh culture medium every 2-3 days.

[0049] (3) Culture of PDLSCs

[0050] 1) Cell passaging: Thoroughly remove the original culture medium in the culture dish, and gently wash the bottom of the culture dish once with a PBS solution preheated to 37°C to remove the residual culture medium. Then add trypsin to ensure that the trypsin evenly covers the bottom of the culture dish, and then place the culture dish in a 37°C incubator for digestion and incubation. When the cell morphology is observed to be round and the cells can be suspended in the liquid when the culture dish is gently shaken, immediately add twice the volume of trypsin containing 10% serum α-MEM culture medium to terminate the digestion process. After that, half-open the lid and tilt the culture dish slightly, and use a pipette to gently and repeatedly blow the cell mixture in the dish to mix the cells evenly. Then, transfer it to a centrifuge tube. To ensure that all cells are collected, you can choose to add an appropriate amount of PBS to the culture dish again to rinse the bottom of the culture dish, and add the rinse solution to the centrifuge tube. Then, spin the centrifuge tube at 1000rpm for 4min. After the centrifugation, carefully remove the supernatant, retain the cell pellet at the bottom, gently resuspend it with 10% serum α-MEM culture medium, and transfer it to a new culture dish. In order to ensure the accuracy and stability of the experiment, the cells used in all experiments of the present invention were 3rd-5th generation PDLSCs.

[0051] 2) Cell plating: Digest the cells according to the cell passage method to obtain cell pellets, resuspend the cells in α-MEM medium containing 10% serum, aspirate part of the cell suspension, dilute it, take 10 μL and add it to the cell counting plate for cell counting and calculate the cell density. According to the specific needs of the experiment, inoculate an appropriate amount of cells into a new culture dish or culture plate, and then proceed with subsequent experimental operations.

[0052] 3) Cell cryopreservation: Digest the cells according to the cell passaging method to obtain a cell pellet, resuspend the cell pellet in a cell freezing solution (serum: DMSO = 9:1) and place it in a cell freezing tube, transfer it to a gradient freezing box, store it at -80°C overnight, and then transfer it to a liquid nitrogen tank for long-term storage.

[0053] 4) Cell recovery: Add enough distilled water to the thermostatic water bath and set the temperature to 37°C. Prepare a foam ice box, take out the required cells from the liquid nitrogen tank, quickly transfer them to the water bath, and gently shake the cryotube to ensure that the cells are evenly dispersed. Then, spin the cryotube at 1000rpm for 4 minutes. Remove the supernatant, resuspend the cell pellet in fresh culture medium and add it to the culture dish. After 24 hours, observe under a microscope and replace with fresh culture medium for subsequent experiments.

[0054] 2. Construction of plasmids overexpressing TEAD1 / 2 / 3 / 4

[0055] The sequences of TEAD1-4 are as follows:

[0056] TEAD1:NCBI Reference Sequence:NM_021961.6

[0057] TEAD2:NCBI Reference Sequence:NM_001256658.2

[0058] TEAD3:NCBI Reference Sequence:NM_001395214.1

[0059] TEAD4:NCBI Reference Sequence:NM_003213.4

[0060] (1) Design primers to clone TEAD1 / 2 / 3 / 4 target fragments

[0061] Table 1 Primer sequences for overexpression of TEAD1 / 2 / 3 / 4

[0062]

[0063] (2) The reaction system and procedure for PCR cloning of the target fragment are as follows: total RNA extracted from human PDLSCs is reverse transcribed and the DNA chain (cDNA) complementary to RNA is used as the template for cloning.

[0064] Table 2 PCR reaction system for cloning target fragments

[0065] Components volume 2×Phanta Max Master Mix 25μL cDNA 3μL OE-hTEAD-F 1μL OE-hTEAD-R 1μL <![CDATA[ddH2O]]> 20μL

[0066] Table 3 PCR reaction conditions for target fragment cloning

[0067]

[0068] (3) Performing DNA gel electrophoresis on the obtained PCR reaction products and recovering the target fragments by cutting the gel;

[0069] (4) Enzyme digestion of vector: After enzyme digestion at 37°C for 30 min, perform DNA gel electrophoresis and cut the gel to recover the vector. The reaction system is as follows:

[0070] Table 4 Reaction system of restriction endonuclease vector

[0071]

[0072] (5) Homologous recombination of the target fragment and the vector: Homologous recombination at 50°C for 30 min. The reaction system is as follows:

[0073] Table 5 Homologous recombination reaction system

[0074]

[0075] (6) Transformation:

[0076] 1) Take out the DH5α competent cells from the -80°C freezer and thaw them on ice;

[0077] 2) Take 5 μL of homologous recombination product, add it to the thawed DH5α, mix well, and let it stand on ice for 20 minutes;

[0078] 3) Place the competent cells in a water bath, heat shock at 42°C for 60 seconds, and quickly transfer to ice for incubation for 2 minutes;

[0079] 4) Add 600 μL of LB solution without ampicillin resistance to the competent cells, place in a 37°C shaker, set the speed to 200 rpm, and shake and culture for 1 hour;

[0080] 5) Centrifuge at 4000 rpm for 5 min at room temperature, discard part of the supernatant, use the retained 200 μL liquid to gently mix the bacterial pellet, evenly spread it on a solid LB plate containing ampicillin resistance, and invert it in a 37°C incubator to incubate overnight; (7) Pick bacteria for testing and extract plasmid: randomly pick 5 single clones from the plate, add them to an EP tube containing 1 mL of ampicillin resistance LB solution, and culture them in a shaker at 200 rpm at 37°C for 6 h. Take 300 μL of the bacterial solution for sequencing. After the results are successfully matched, expand the culture to extract the plasmid, and the plasmid construction is completed.

[0081] 3. Construction of TEAD1 / 2 / 3 / 4 knockdown plasmids

[0082] (1) Design of primer sequences for knockdown of TEAD1 / 2 / 3 / 4:

[0083] Table 6 Primer sequences for knocking down TEAD1 / 2 / 3 / 4

[0084]

[0085] (2) Primer annealing reaction system and procedure:

[0086] Table 7 Primer annealing reaction system

[0087]

[0088] Table 8 Primer annealing reaction program

[0089]

[0090] (3) Enzyme digestion of vector: After enzyme digestion at 37°C for 30 min, perform gel electrophoresis and cut the gel to recover the vector. The system is as follows;

[0091] Table 9 Reaction system of restriction endonuclease vector

[0092]

[0093] (4) Ligate the target fragment to the vector: 25°C for 2 h, the system is as follows;

[0094] Table 10T4 ligase reaction system

[0095]

[0096] (5) Transformation, bacterial selection, and plasmid extraction: The steps are the same as those for the construction of TEAD1 / 2 / 3 / 4 overexpression plasmids.

[0097] 4. Construction of PDLSCs with stable overexpression or knockdown of TEAD1 / 2 / 3 / 4

[0098] (1) Packet virus:

[0099] When the growth density of 293T cells in a 10 cm culture dish reaches about 80%, virus packaging is performed and the culture medium is replaced with serum-free DMED (empty culture). Take a sterile centrifuge tube, add 500 μL of empty culture and the following plasmids, and take another sterile centrifuge tube and add 500 μL of empty culture and 10 μL of PEI. After mixing the two mixtures, let them stand at room temperature for 10 minutes. Subsequently, mix the liquids in the two centrifuge tubes and continue to stand for 15 minutes. Next, slowly add the mixture dropwise to the culture dish and place it in a 37°C incubator for 6-8 hours. Discard the old culture medium and continue to culture with DMED containing 10% inactivated serum (FBS in a 55°C water bath for 30 minutes). Collect the virus supernatant once every 24 hours.

[0100] Table 11 Virus packaging system

[0101]

[0102] (2) Infection of PDLSCs:

[0103] After cell digestion and centrifugation, resuspend the cells in culture medium (without serum), add virus and Polybrene to the cell suspension, discard the original culture medium after 24 hours of infection, add α-MEM culture medium containing 10% serum, and change the medium after 48 hours of culture and add puromycin (2μg / mL) for cell screening. After the cells are full, digestion and passage can be used for subsequent detection. Refer to Clontech LentiX_Lentiviral Expression Systems to induce the expression of the corresponding gene.

[0104] 5. Construction of PDLSCs stably overexpressing TEAD3 and TEAi

[0105] (1) TEAi plasmid construction: synthesize the protein polypeptide TEAi and connect it to the vector with GFP (pLVX-AcEGFP-N1), transform the plate, pick a single clone and send it for sequencing, extract the plasmid after successful sequence alignment, and the plasmid construction is completed;

[0106] (2) Encapsulated virus TEAi: The method is the same as in Part 4.

[0107] (3) Construction of PDLSCs overexpressing TEAD3: The method is the same as in Part 4.

[0108] (4) Infection with TEAi: Take 1 / 2 of the PDLSCs in step (3) and infect them with TEAi in the same way to ensure that the expression level of TEAD3 in the TEAi group is consistent with that in the non-TEAi infected group. After the cells are fully grown, they are used for subsequent experiments.

[0109] VI. Osteogenic differentiation induction and detection

[0110] (1) Preparation of osteogenic induction medium:

[0111] The main components are 10nmol / L dexamethasone, 50mg / L ascorbic acid and 10mmol / L β-sodium glycerophosphate, and the solvent is α-MEM culture medium containing 10% serum.

[0112] (2) Osteogenic differentiation induction

[0113] PDLSCs with good growth status were evenly spread in the well plate, and when the cell density reached 80%, the medium was replaced with osteogenic induction medium, and the medium was changed every three days. ALP staining and activity detection were performed on the 7th day of osteogenic induction, and Alizarin red staining and calcium ion concentration quantification were performed on the 14th day of osteogenic induction.

[0114] (3) ALP staining

[0115] First, prepare the ALP staining solution according to the instructions. Remove the original culture medium in the well plate and wash it once with PBS. Fix it with 4% tissue cell fixative at room temperature for 15 minutes, and then wash it again with PBS. Cover the surface of the well plate evenly with the ALP staining solution. Cover the well plate with tin foil and incubate it at room temperature in the dark for 30 minutes. Then, aspirate the staining working solution, add an appropriate amount of distilled water to clean the well plate, observe the staining results of the well plate with the naked eye, take and keep the overall photo of the well plate, and observe and take photos under an inverted microscope.

[0116] (4) ALP activity detection

[0117] Protein was extracted from PDLSCs after 7 days of osteogenic induction. After determining the protein concentration, the samples were added to a 96-well plate according to the instructions. After sufficient mixing, the plates were incubated at 37°C for 15 min. The absorbance at a wavelength of 520 nm was measured by an enzyme-labeled instrument, and the data were calculated and statistically analyzed.

[0118] (5) Alizarin red staining and calcium ion concentration quantification

[0119] Remove the culture medium from the well plate, wash once with PBS, fix the cells at room temperature for 15 minutes with 4% tissue cell fixative, wash once with PBS, remove excess liquid, add alizarin red dye to the well plate to cover the bottom of the dish, dye for 15 minutes, then discard the dye, and wash with PBS. Observe the well plate staining results with the naked eye, take and retain the overall photos of the well plate, and observe and take photos under an inverted microscope. After the photo collection is completed, add a 10% cetylpyridinium chloride (Cetylpyridinium chloride, CPC) solution to each group and blow and mix, let stand at room temperature for 15 minutes, take 100 μL of the mixture from each group and add it to a 96-well plate, use an enzyme reader to measure the absorbance value at a wavelength of 562nm, calculate the data and perform statistical analysis.

[0120] VII. RNA Extraction

[0121] (1) Take the treated cells, discard the original culture medium, wash twice with PBS, add TRIzol solution directly to the culture dish, lyse at room temperature for 10 minutes, and transfer the lysate to a nuclease-free EP tube;

[0122] (2) Perform the subsequent steps in a clean bench. Add chloroform reagent to the TRIzol solution in proportion (200 μL chloroform per 1 mL TRIzol), shake up and down vigorously for 30 seconds to mix, and incubate at room temperature for 10 minutes.

[0123] (3) Place in a 4°C centrifuge and centrifuge at 12,000 rpm for 10 min (the solution is divided into three layers, the bottom layer is a red phenol-chloroform phase, the middle layer is a white boundary phase, and the upper layer is a transparent aqueous phase. RNA is in the upper aqueous phase). Use a pipette to gently aspirate the upper aqueous phase and transfer it to a new nuclease-free EP tube;

[0124] (4) After aspirating the upper aqueous phase, add an equal volume of isopropanol and mix gently. Then, incubate on ice for 15 min. Place the mixture in a 4°C centrifuge and centrifuge at 12,000 rpm for 30 min. At this time, a white RNA precipitate can be observed at the bottom of the tube.

[0125] (5) After removing the supernatant, add 1 mL of 75% ethanol to wash the white RNA precipitate. Place the EP tube in a 4°C centrifuge again, spin at 12,000 rpm for 10 min, and repeat the washing step;

[0126] (6) After washing, carefully remove the supernatant and open the lid of the tube containing the RNA precipitate. Let it stand at room temperature to dry until the white RNA precipitate in the tube becomes translucent. Add 20-50 μL of DEPC water to fully dissolve the RNA precipitate. Place the final RNA solution on ice, measure the RNA concentration, and store it at -20°C.

[0127] 8. RNA Reverse Transcription

[0128] The extracted RNA was converted into cDNA according to the following system:

[0129] Table 1 RNA inversion system

[0130] Components volume RNA template ≤1μg total RNA StarScriptIIIAll-in-OneRTMix 1μL 5×StarScriptIIIAll-in-OneRTBuffer 4μL Nuclease-freeWater(DEPC-treated) Make up to 20 μL

[0131] Table 2 RNA inversion reaction conditions

[0132] temperature time 37℃ 2min 50℃ 15min 85℃ 2min

[0133] The cDNA obtained after the reaction can be used for the next experiment or stored at -20℃.

[0134] IX. Real-time fluorescence quantitative PCR

[0135] (1) Dilute the cDNA obtained by reverse transcription 10 times using high pressure Milli-Q water and add it to the eight-well plate according to the following table system:

[0136] Table 3 Real-time fluorescence quantitative PCR reaction system

[0137] Components volume ChamQuniversalSYBRQPCRMaster 5μL ForwardPrimer 0.5μL(10μM) ReversePrimer 0.5μL(10μM) cDNA 4μL

[0138] (2) After the above system is prepared, the eight strips are centrifuged instantaneously and placed in a PCR instrument in sequence. The reaction program is set as follows (40 cycles):

[0139] Table 4 Real-time fluorescence quantitative PCR reaction conditions

[0140] temperature time 95℃ 30s 95℃ 15s 60℃ 30s

[0141] (3) The obtained data were analyzed using the ΔΔCt method.

[0142] (4) Gene primer sequences used in real-time quantitative PCR:

[0143] Table 5 Primer sequences

[0144]

[0145]

[0146] 10. Construction of Rat Skull Defect Model

[0147] (1) Experimental groups

[0148] Fifteen healthy male SD rats aged 6-8 weeks were selected and adaptively fed for 2 weeks. They were randomly divided into three groups and bilateral skull defects were prepared in the rats.

[0149] 1) Control: simple bone defect group;

[0150] 2) Scaffolds: only the bearing material group (Pluronic F-127 + gelatin sponge) was implanted in the bone defect area;

[0151] 3) Vector: PDLSCs overexpressing Vector + material group were implanted into the bone defect area;

[0152] 4) TEAi: PDLSCs overexpressing TEAi + material group were implanted into the bone defect area;

[0153] 5) OE-TEAD3: PDLSCs overexpressing TEAD3 + material group were implanted into the bone defect area;

[0154] 6) OE-TEAD3+TEAi: PDLSCs+material group overexpressing TEAD3+TEAi were implanted into the bone defect area;

[0155] (2) Cell and material preparation

[0156] 1) Preparation of gelatin sponge loaded with PDLSCs:

[0157] In a sterile clean bench, gelatin sponges were cut into 2 mm × 2 mm × 2 mm sizes and placed in each well of a 96-well plate. Then, 0.75 mg / L poly-D-lysine solution (PLL) was added to the gelatin sponges and placed in a 37°C incubator overnight. PLL was removed and washed 3 times with PBS and once with osteogenic induction medium. Then, the gelatin sponges were soaked in osteogenic induction medium overnight. The original medium was removed and the treated cell suspension (cells resuspended in osteogenic induction medium) was added to the pretreated gelatin sponges (200 uL). The experiment was carried out after 3 days of culture. The concentration of the cell suspension was 1.5 × 10 6 Pieces / mL.

[0158] 2) Preparation of Pluronic F-127 gel loaded with PDLSCs:

[0159] Weigh 5 g of Pluronic F-127 (polyoxyethylene polyoxypropylene ether) powder into a 50 mL centrifuge tube and add water to 25 mL. Stir thoroughly at 4°C to mix evenly. Pluronic F-127 is liquid at 4°C. Pour it into a petri dish and sterilize it with ultraviolet light overnight. After the disinfection is completed, store it in aliquots.

[0160] On the day of modeling, the treated cells were digested and centrifuged, washed once with PBS, the supernatant was discarded, and the cells were resuspended in EP tubes with Pluronic F-127 pre-cooled at 4°C and kept on ice for later use. The concentration of the cell suspension was 1.5×10 6 / mL, heated in a 37℃ water bath into a gel state and then placed into the bone defect area.

[0161] (3) Preparation of rat skull defect model

[0162] 1) Anesthesia: Rats were fasted for 12 h before surgery and anesthetized with 3-4% isoflurane gas, and 1.5-2% isoflurane was used for maintenance during surgery;

[0163] 2) Skin preparation: Use a hair removal knife to prepare the skin of the surgical site and use iodine to disinfect the surgical area;

[0164] 3) Incision and preparation of bone defect: A vertical incision was made in the middle of the scalp to expose the skull. A slow-speed trephine bone knife was then used to create a full-thickness bone defect with a diameter of 5 mm on both sides of the skull. During the operation, 0.9% sodium chloride injection was used to flush the wound and cool it, and the vital signs of the rats were closely monitored throughout the operation;

[0165] 4) Treatment of bone defect area: referring to the method of Professor Liu Yi (Liu, Y., et al., Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α. Nat Med, 2011. 17(12): p. 1594-601.), according to the preoperative grouping, the prepared Pluronic F-127 gel loaded with PDLSCs was accurately placed in the skull defect area, and the gelatin sponge loaded with PDLSCs was implanted on top to fix the gel below. The same group of materials and PDLSCs were placed in the bilateral bone defect areas of each rat;

[0166] 5) Suture and disinfection: reposition and suture, and disinfect the surgical area.

[0167] (4)Acquisition of materials

[0168] Twelve weeks after surgery, the rats were killed by cervical dislocation after 3-4% isoflurane gas anesthesia. The skin was cut open to expose the skull, which was cut along the edge of the skull base to remove the surrounding soft tissues. The prepared skull defect area was completely removed and fixed in 4% tissue fixative.

[0169] 11. Micro-CT Scanning

[0170] The fixed tissue was scanned by Micro-CT with a layer thickness of 0.2 μm. The tissue was reconstructed in three dimensions using CTVox software and analyzed using CTAn software to calculate the bone volume fraction (Bone volume / Tissue volume, BV / TV), trabecular number (Trabecular number, Tb.N), trabecular thickness (Trabecular thickness, Tb.Th) and trabecular separation (Trabecular separation, Tb.Sp) in the bone defect area.

[0171] 12. Decalcification, embedding and sectioning

[0172] (1) Decalcification: Soak the skull tissue in EDTA decalcification solution and place it on a shaker to accelerate decalcification. Replace the solution with fresh decalcification solution every 3 days. After 1 month of decalcification, use a needle tip to test. When it can penetrate the tissue without resistance, it indicates that the decalcification effect has been achieved.

[0173] (2) Embedding: Use a dehydrator to dehydrate the tissue and immerse it in 50%, 70%, 80%, 95% and 100% ethanol by volume. Then use xylene for transparency and immerse it in xylene in sequence. Finally, immerse the skull tissue completely in wax liquid to ensure that the wax liquid fully penetrates, wrap the processed skull tissue tightly in the wax block, and store the tissue at 4°C after embedding for later use.

[0174] (3) Sectioning: Use a microtome to slice paraffin tissue. Control the direction to be perpendicular to the rat skull tissue, and make continuous sections starting from the defect edge. Finally, take the largest diameter of the skull defect, then stick it on a slide, dry it in a 60°C oven, and store it at 4°C for later use.

[0175] 13. Hematoxylin-eosin staining (HE)

[0176] (1) Gradient rehydration: The steps are as follows:

[0177] 1) Xylene 115min

[0178] 2) Xylene II 15min

[0179] 3) 100% ethanol I 5 min

[0180] 4) 100% ethanol II 5 min

[0181] 5) 95% ethanol I 5min

[0182] 6) 95% ethanol II 5 min

[0183] 7) 80% ethanol for 5 min

[0184] 8) 70% ethanol for 5 min

[0185] 9) Distilled water for 5 minutes

[0186] (2) Hematoxylin staining of cell nuclei: Take out the slices, carefully remove excess liquid on the surface with filter paper, add hematoxylin staining solution and incubate at room temperature for 3-5 minutes until the cell nuclei appear blue-purple, rinse with distilled water to remove excess staining solution;

[0187] (3) Hydrochloric acid differentiation treatment: Place the slices in hydrochloric acid differentiation solution for about 20 seconds to remove excess staining and make the staining of the cell nucleus clearer;

[0188] (4) Ammonia blueing: Place the slice in ammonia blueing solution for about 20 seconds to make the blue color of the cell nucleus more obvious;

[0189] (5) Eosin staining of cytoplasm: Take out the slices, carefully remove excess liquid on the surface with filter paper, add eosin staining solution and incubate at room temperature for 1-2 min until the cytoplasm turns purple-red, and remove excess staining solution with distilled water;

[0190] (6) Gradient dehydration:

[0191] 1) Distilled water 5-10s

[0192] 2) 70% ethanol 5-10s

[0193] 3) 80% ethanol 5-10s

[0194] 4) 95% ethanol II 5-10s

[0195] 5) 95% ethanol I 5-10s

[0196] 6) 100% ethanol II 2 min

[0197] 7) 100% ethanol I 2 min

[0198] 8) Xylene II 5min

[0199] 9) Xylene 1 5min

[0200] (7) Use neutral gum to seal the slices after dehydration;

[0201] (8) Observe the stained sections under a microscope and perform image acquisition and analysis.

[0202] 14. Masson staining

[0203] (1) The gradient rehydration process is the same as HE staining;

[0204] (2) Prepare Weigert iron hematoxylin staining solution in advance according to the product instructions, add it evenly onto the tissue section, and stain for 5-10 minutes;

[0205] (3) Rinse with distilled water to remove excess staining solution. Then, add acidic ethanol differentiation solution for differentiation for 5-15 seconds. After differentiation is completed, rinse with distilled water for 30 seconds;

[0206] (4) Use Masson bluing solution for 3-5 minutes. After bluing, rinse with distilled water for 30 seconds.

[0207] (5) Immerse the sections in Ponceau fuchsin staining solution for 5-10 min;

[0208] (6) Add the weak acid working solution prepared in advance according to the proportion to the slice and let it act for 30 seconds;

[0209] (7) After removing the excess liquid, add phosphomolybdic acid solution for treatment for 1-2 minutes. After the treatment is completed, rinse again with weak acid working solution for 30 seconds;

[0210] (8) Remove excess liquid, then add aniline blue staining solution for staining for 1-2 minutes. After staining, rinse again with weak acid working solution for 30 seconds;

[0211] (9) Gradient dehydration and HE staining;

[0212] (10) Use neutral gum to seal the slices after dehydration;

[0213] (11) Observe under a microscope and take photos.

[0214] 15. Immunohistochemistry (IHC) staining

[0215] (1) Baking: Place the tissue slices in a 60°C oven and bake for 3-6 hours;

[0216] (2) The gradient rehydration process is the same as HE staining;

[0217] (3) Antigen repair: Soak the tissue sections in sodium citrate antigen repair solution, heat in a microwave for 6 minutes until the liquid boils, take it out and let it cool to room temperature, then heat it again until it boils, and repeat this step 6 times. Finally, place the sections in the repair solution at room temperature for about 1 hour and cool to room temperature;

[0218] (4) Blocking endogenous peroxidase: Take out the tissue slices, carefully remove the excess liquid on the surface with filter paper, add endogenous peroxidase blocker, incubate at room temperature for 10 minutes, remove the liquid on the surface of the slices, and wash with PBS three times;

[0219] (5) Blocking: Remove the liquid on the surface of the slice, add 1% BSA, and place in a wet box at 37°C for 1 h;

[0220] (6) Incubation with primary antibody: remove the slices and drain the surface liquid, add 20 μl of antibody (1% BSA diluted according to the instructions, cover the tissue site with sealing film, place in a wet box, incubate at 4°C overnight, warm the wet box to room temperature for 1-2 hours the next day, wash with PBS three times, 3 minutes each time;

[0221] (7) Reaction enhancement solution: drain the surface liquid, add an appropriate amount of reaction enhancement solution, place in a wet box and incubate at room temperature for 20 min, wash with PBS three times, 3 min each time;

[0222] (8) Incubation with secondary antibody: drain the surface liquid, add the corresponding enhanced enzyme-labeled goat anti-rabbit / mouse IgG polymer, and incubate in a wet box at room temperature for 20 min. Wash with PBS three times, 3 min each time;

[0223] (9) DAB color development solution: drain the surface liquid, add the diluted DAB color development solution, and incubate at room temperature for about 10 minutes until color is developed. Drain the surface liquid and wash with PBS three times, 3 minutes each time;

[0224] (10) Hematoxylin counterstaining of cell nuclei: drain the surface liquid, add hematoxylin staining solution, and incubate at room temperature for 5 min until the cell nuclei turn blue-purple. Drain the surface liquid and wash with distilled water three times, 3 min each time;

[0225] (11) Hydrochloric acid differentiation: Drain the surface liquid and place the slices in hydrochloric acid differentiation solution for about 20 seconds;

[0226] (12) Ammonia bluing: Drain the surface liquid and place the slice in ammonia bluing solution for about 20 seconds;

[0227] (13) Gradient dehydration and sealing: The steps are the same as HE staining.

[0228] Related test results and discussion:

[0229] 1. Effect of TEAD on the osteogenic differentiation ability of PDLSCs

[0230] In order to explore the effect of overexpression of TEAD on the osteogenic differentiation ability of PDLSCS, five groups of cells, OE-Vector, OE-TEAD1, OE-TEAD2, OE-TEAD3 and OE-TEAD4, were simultaneously induced to osteogenetically.

[0231] ALP staining and ALP activity detection were performed 7 days after osteogenic induction. The results showed that compared with the OE-Vector group, the staining depth of cells in the OE-TEAD1, OE-TEAD2, OE-TEAD3 and OE-TEAD4 groups was significantly reduced, and the ALP activity was significantly downregulated ( Figure 1 A). Alizarin red staining and CPC calcium ion concentration quantitative analysis were performed 14 days after osteogenic induction. The results showed that compared with the OE-Vector group, the formation of cell mineralized nodules in the OE-TEAD1, OE-TEAD2, OE-TEAD3 and OE-TEAD4 groups was significantly reduced, and the calcium ion concentration was significantly reduced ( Figure 1 B). In addition, compared with the OE-Vector group, the mRNA expression levels of ALP, COL1A1, OSX and OPN in the four groups of cells, OE-TEAD1, OE-TEAD2, OE-TEAD3 and OE-TEAD4, were significantly decreased ( Figure 1 C). The above results showed that compared with the OE-Vector group, the osteogenic differentiation ability of cells in the four groups of OE-TEAD1, OE-TEAD2, OE-TEAD3 and OE-TEAD4 was reduced, that is, overexpression of TEAD inhibited the osteogenic differentiation ability of PDLSCs.

[0232] In order to explore the effect of TEAD knockdown on the osteogenic differentiation ability of PDLSCs, we simultaneously induced osteogenic differentiation in five groups of cells: shScr, shTEAD1, shTEAD2, shTEAD3 and shTEAD4.

[0233] ALP staining and ALP activity detection were performed 7 days after osteogenic induction. The results showed that compared with the shScr group, the staining depth of cells in the shTEAD1, shTEAD2, shTEAD3 and shTEAD4 groups were significantly enhanced, and the ALP activity was significantly increased ( Figure 2 A). Alizarin red staining and quantitative analysis of CPC calcium ion concentration were performed 14 days after osteogenic induction. The results showed that compared with the shScr group, the formation of cell mineralized nodules in the shTEAD1, shTEAD2, shTEAD3 and shTEAD4 groups increased significantly, and the calcium ion concentration was significantly increased ( Figure 2B). In addition, compared with the shScr group, the mRNA expression levels of ALP, COL1A1, OSX and OPN in the shTEAD1, shTEAD2, shTEAD3 and shTEAD4 groups were significantly increased ( Figure 2 C). The above results showed that compared with the shScr group, the osteogenic differentiation ability of cells in the shTEAD1, shTEAD2, shTEAD3 and shTEAD4 groups was enhanced, that is, knocking down TEAD promoted the osteogenic differentiation ability of PDLSCs.

[0234] In summary, TEAD negatively regulates the osteogenic differentiation ability of PDLSCs. Therefore, targeted inhibition of TEAD can theoretically promote the osteogenic differentiation of PDLSCs.

[0235] 2. Effect of TEAi, a protein peptide that targets and inhibits TEAD, on the osteogenic differentiation ability of PDLSCs

[0236] The present invention designs a protein polypeptide TEAi that targets and inhibits TEAD to achieve the purpose of promoting osteogenic differentiation of PDLSCs. First, in order to explore the effect of TEAi on the osteogenic differentiation ability of PDLSCs, the present invention simultaneously cultured PDLSCs in the Vector, TEAi, OE-TEAD3 and OE-TEAD3+TEAi groups for osteogenic induction.

[0237] ALP staining and ALP activity detection were performed on the 7th day of osteogenic induction. The results showed that compared with the control group Vector, the ALP staining depth of the TEAi expression group was significantly increased, and the ALP activity was significantly enhanced. In addition, compared with the OE-TEAD3 group, the ALP staining depth of PDLSCs in the OE-TEAD3+TEAi group was significantly increased, and the ALP activity was significantly enhanced ( Figure 3 A). Alizarin red staining and quantitative analysis of CPC calcium ion concentration were performed on day 14 of osteogenic induction. The results showed that compared with the control group Vecrot, the formation of mineralized nodules in the TEAi-expressing group increased significantly, and the calcium ion concentration increased significantly. In addition, compared with the OE-TEAD3 group, the formation of mineralized nodules in PDLSCs in the OE-TEAD3+TEAi group increased significantly, and the calcium ion concentration increased significantly ( Figure 3 B). At the same time, compared with the control group Vector, the mRNA expression levels of osteogenic-related genes ALP, OCN, OSX and OPN in the TEAi-expressing group were significantly increased. Compared with the OE-TEAD3 group, the mRNA expression levels of osteogenic-related genes ALP, OCN, OSX and OPN in PDLSCs in the OE-TEAD3+TEAi group were significantly increased ( Figure 3C). The above results show that TEAi can significantly promote the osteogenic differentiation of PDLSCs, and TEAi can reverse the inhibitory effect of TEAD3 on the osteogenic differentiation of PDLSCs.

[0238] 3. Effect of TEAi, a protein peptide that targets TEAD, on PDLSCs-mediated bone tissue regeneration in vivo

[0239] (I) Establishment of rat skull defect model

[0240] Full-thickness bone defects with a diameter of 5 mm were successfully prepared on both sides of the rat skull. Pluronic F-127 gel loaded with PDLSCs and gelatin sponge loaded with PDLSCs were implanted, and the wounds were sutured ( Figure 4 ).

[0241] (II) Micro-CT analysis of the effect of TEAi on the new bone formation ability in the bone defect area

[0242] Twelve weeks after surgery, the bone defect area of ​​the rat skull was scanned using Micro-CT and three-dimensionally reconstructed ( Figure 5 A). At the same time, the new bone in the bone defect area of ​​each group was statistically analyzed ( Figure 5 B).

[0243] The results showed that compared with the control group Vector, the bone volume fraction (Bone volume / Tissue volume, BV / TV) of the TEAi expression group was significantly increased, indicating that the formation of new bone in the bone defect area of ​​the TEAi expression group was significantly increased; at the same time, the results of bone quality analysis showed that the trabecular thickness (Trabecular thickness, Tb.Th) and trabecular number (Trabecular number, Tb.N) were significantly increased, while the trabecular separation (Trabecular separation, Tb.Sp) was significantly reduced, indicating that the new bone tissue in the TEAi expression group was denser ( Figure 5 B). At the same time, compared with the control group Vector, the BV / TV, Tb.Th and Tb.N of the OE-TEAD3 group were significantly reduced, while Tb.Sp was significantly increased. The above results show that TEAi can significantly increase the amount of bone tissue regeneration mediated by PDLSCs in vivo and significantly improve the quality of bone tissue, while TEAD3 significantly inhibits the amount of bone tissue regeneration mediated by PDLSCs in vivo and significantly reduces the quality of bone tissue.

[0244] In addition, compared with the OE-TEAD3 group, the BV / TV, Tb.Th and Tb.N of the OE-TEAD3+TEAi group were significantly increased, while Tb.Sp was significantly decreased, indicating that the amount of new bone tissue in the OE-TEAD3+TEAi group was larger and denser ( Figure 5 B).

[0245] The above results indicate that TEAi can significantly increase the amount of PDLSCs-mediated bone tissue regeneration in vivo, significantly improve the quality of bone tissue, and TEAi can reverse the inhibitory effect of TEAD3 on PDLSCs-mediated bone tissue regeneration in vivo.

[0246] (III) Tissue staining to detect the effect of TEAi on the regeneration capacity of bone tissue in the bone defect area

[0247] HE staining results of paraffin sections of rat skull bone defect tissue showed that the bone defect area was filled with collagen-like tissue and newly formed mineralized bone tissue ( Figure 6 A). The comparison results showed that compared with the control group Vector, the new bone formation in the bone defect area of ​​the TEAi expression group increased significantly, and the structure was more densely woven, while the new bone formation in the bone defect area of ​​the OE-TEAD3 group decreased significantly, and the structure was more sparse, indicating that TEAi can significantly promote the ability of PDLSCs-mediated new bone formation in vivo, while TEAD3 significantly inhibits the ability of PDLSCs-mediated new bone formation in vivo. In addition, compared with the OE-TEAD3 group, the new bone formation in the bone defect area of ​​the OE-TEAD3+TEAi group increased significantly, and the structure was more densely woven, indicating that TEAi can reverse the inhibitory effect of TEAD3 on the ability of PDLSCs-mediated new bone formation in vivo ( Figure 6 A).

[0248] Masson staining of paraffin sections of rat skull bone defect tissue showed that new trabeculae and collagen fibers were formed at the edge of the skull defect ( Figure 6 B). The comparison results showed that compared with the control group Vector, the mineralization degree of bone tissue in the bone defect area of ​​the TEAi expression group was significantly improved, and the formation of collagen fibers was significantly increased, while the mineralization degree of bone tissue in the bone defect area of ​​the OE-TEAD3 group was significantly reduced, and the formation of collagen fibers was significantly reduced, indicating that TEAi can significantly improve the mineralization degree of new bone tissue mediated by PDLSCs in vivo, while TEAD3 significantly inhibits the mineralization degree of new bone tissue mediated by PDLSCs in vivo. In addition, compared with the OE-TEAD3 group, the mineralization degree of bone tissue in the bone defect area of ​​the OE-TEAD3+TEAi group was significantly improved, and the formation of collagen fibers was significantly increased, indicating that TEAi can reverse the inhibitory effect of TEAD3 on the mineralization of new bone tissue mediated by PDLSCs in vivo ( Figure 6 B).

[0249] OPN immunohistochemical staining was performed on paraffin sections of rat skull bone defect tissue to observe the expression level of OPN in the bone defect area of ​​each group ( Figure 6 C). The comparison results showed that compared with the control group Vector, the OPN expression level in the bone defect area of ​​the TEAi expression group was significantly increased, while the OPN expression level in the bone defect area of ​​the OE-TEAD3 group was significantly decreased. In addition, compared with the OE-TEAD3 group, the OPN expression level in the bone defect area of ​​the OE-TEAD3+TEAi group was significantly increased ( Figure 6 C).

[0250] The above results indicate that TEAi can significantly enhance the in vivo bone tissue regeneration effect mediated by PDLSCs, and TEAi can reverse the inhibitory effect of TEAD3 on the in vivo bone tissue regeneration effect mediated by PDLSCs.

[0251] Although the embodiments of the present invention are disclosed for illustrative purposes, those skilled in the art will appreciate that various substitutions, changes and modifications are possible without departing from the spirit and scope of the present invention and the appended claims. Therefore, the scope of the present invention is not limited to the contents disclosed in the embodiments.

Claims

1. A TEAD inhibitory protein polypeptide TEAi for bone tissue regeneration, characterized in that: The amino acid sequence of TEAi is: SEQ ID NO.

1.

2. The TEAi according to claim 1, characterized in that: The TEAi can significantly promote the osteogenic differentiation of human periodontal ligament stem cells PDLSCs, and TEAi can reverse the inhibitory effect of TEAD on the osteogenic differentiation of PDLSCs.

3. The TEAi according to claim 1, characterized in that: The TEAi can reverse the inhibitory effect of TEAD3 on the in vivo new bone formation ability mediated by PDLSCs.

4. The TEAi according to claim 1, characterized in that: The TEAi can reverse the inhibitory effect of TEAD3 on the mineralization of new bone tissue mediated by PDLSCs in vivo.

5. Use of the TEAi according to any one of claims 1 to 4 in bone tissue regeneration.

6. The use according to claim 5, characterized in that: The bone tissue regeneration is the osteogenic differentiation of human periodontal ligament stem cells and the in vivo bone tissue regeneration mediated by the same.

7. Use of the TEAi according to any one of claims 1 to 4 in the preparation of a medicament and / or product and / or preparation for bone tissue regeneration.

8. Use of the TEAi according to any one of claims 1 to 4 in the preparation of a medicament and / or product and / or preparation for osteogenic differentiation of human periodontal ligament stem cells and the in vivo bone tissue regeneration mediated by the same.

Citation Information

Patent Citations

  • Polypeptide and application thereof in promoting bone repair

    CN114853852A

  • TEAD inhibitory polypeptide and application thereof

    CN118852396A